[go: up one dir, main page]

MX2017008430A - Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada. - Google Patents

Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.

Info

Publication number
MX2017008430A
MX2017008430A MX2017008430A MX2017008430A MX2017008430A MX 2017008430 A MX2017008430 A MX 2017008430A MX 2017008430 A MX2017008430 A MX 2017008430A MX 2017008430 A MX2017008430 A MX 2017008430A MX 2017008430 A MX2017008430 A MX 2017008430A
Authority
MX
Mexico
Prior art keywords
methods
fused bicyclic
preparing fused
diaminopyrimidine derivatives
diaminopyrimidine
Prior art date
Application number
MX2017008430A
Other languages
English (en)
Inventor
P Bakale Roger
P Allwein Shawn
E Petrillo Daniel
KLUWER Sander
R Mowrey Dale
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2017008430A publication Critical patent/MX2017008430A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción está dirigida a métodos mejorados útiles para la preparación de, por ejemplo, 2-[[5-cloro-2-[[(6S)-6-[4-(2- hidroxietil)piperazina-1-il]-1-metoxi-6,7,8,9-tetrahidro-5Hbenzo[ 7]anuleno-2-il]amino]-irimidina-4-il]amino]-N-metil-benzamida (CEP-37440).
MX2017008430A 2014-12-23 2015-12-23 Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada. MX2017008430A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462095861P 2014-12-23 2014-12-23
PCT/US2015/000301 WO2016105529A1 (en) 2014-12-23 2015-12-23 Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2017008430A true MX2017008430A (es) 2018-03-23

Family

ID=55221488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008430A MX2017008430A (es) 2014-12-23 2015-12-23 Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.

Country Status (9)

Country Link
US (1) US10259794B2 (es)
EP (1) EP3237408B1 (es)
JP (1) JP6849594B2 (es)
CA (1) CA2971415A1 (es)
ES (1) ES2707123T3 (es)
HK (1) HK1244789B (es)
IL (1) IL252945B (es)
MX (1) MX2017008430A (es)
WO (1) WO2016105529A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102068374B1 (ko) * 2012-03-06 2020-01-20 세파론, 인코포레이티드 이중 alk 및 fak 억제제로서의 융합된 비시클릭 2,4-디아미노피리미딘 유도체
AU2014236820B2 (en) 2013-03-14 2018-08-02 Sumitomo Pharma Oncology, Inc. JAK2 and ALK2 inhibitors and methods for their use
WO2019195753A1 (en) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01149775A (ja) * 1987-12-07 1989-06-12 Kawaken Fine Chem Co Ltd 光学活性２−メチルピペラジンの製造方法
CN101679237A (zh) * 2007-05-03 2010-03-24 赛福伦公司 制备(r)-2-甲基吡咯烷和(s)-2-甲基吡咯烷及其酒石酸盐的方法
EP2062906A1 (en) 2007-11-22 2009-05-27 Universiteit van Amsterdam Coordination complex system comprising tautomeric ligands
KR102068374B1 (ko) 2012-03-06 2020-01-20 세파론, 인코포레이티드 이중 alk 및 fak 억제제로서의 융합된 비시클릭 2,4-디아미노피리미딘 유도체

Also Published As

Publication number Publication date
EP3237408A1 (en) 2017-11-01
JP6849594B2 (ja) 2021-03-24
IL252945A0 (en) 2017-08-31
CA2971415A1 (en) 2016-06-30
US20170369451A1 (en) 2017-12-28
HK1244789B (en) 2019-12-06
EP3237408B1 (en) 2018-10-31
JP2018507173A (ja) 2018-03-15
IL252945B (en) 2020-05-31
WO2016105529A1 (en) 2016-06-30
US10259794B2 (en) 2019-04-16
ES2707123T3 (es) 2019-04-02

Similar Documents

Publication Publication Date Title
IL279910A (en) Crystal forms of 5-chloro-ene 4-[2-(dimethylphosphoryl)phenyl]-ene 2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-2- 4-diamine
PH12020550703A1 (en) Sulfonamide compounds and use thereof
PH12018501643A1 (en) Tlr7 agonist crystalline form a, preparation method and use thereof
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
NZ630251A (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA201690303A1 (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНОВ ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
NZ727996A (en) Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncytial virus infections
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
SA518400333B1 (ar) شكل متعدد الأشكال من n- {6-(2-هيدروكسي بروبان-2-يل) -2-[2-(مثيل سلفونيل) إثيل]-2h-إندازول-5-يل}-6-(ثلاثي فلورومثيل) بيريدين-2-كربوكساميد
UY34219A (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
PH12015501363A1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
NZ722624A (en) Fused pyrimidines as inhibitors of p97 complex
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
PH12018501641A1 (en) Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses
JOP20150179B1 (ar) مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
EP4606784A3 (en) Co-crystals, salts and solid forms of tenofovir alafenamide
JOP20150177B1 (ar) مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CL2016000387A1 (es) Derivados de amida como antagonistas de ácido receptor lisofosfatidico
MX2017008430A (es) Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.
PH12018502246A1 (en) Substituted fused pyrimidinone compounds
TWD175704S (zh) 化粧瓶用補充用容器
IN2013MU02612A (es)

Legal Events

Date Code Title Description
FG Grant or registration